BR0015194A - Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial - Google Patents

Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial

Info

Publication number
BR0015194A
BR0015194A BR0015194-7A BR0015194A BR0015194A BR 0015194 A BR0015194 A BR 0015194A BR 0015194 A BR0015194 A BR 0015194A BR 0015194 A BR0015194 A BR 0015194A
Authority
BR
Brazil
Prior art keywords
transformation
egfr
reduce
kinase inhibitor
epithelial cells
Prior art date
Application number
BR0015194-7A
Other languages
English (en)
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of BR0015194A publication Critical patent/BR0015194A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UM INIBIDOR DE EGFR-TIROSINA-QUINASE, E, MéTODOS PARA REDUçãO DA TRANSFORMAçãO DE CéLULAS EPITELIAIS E PARA CAUSAR REVERSãO SUBSTANCIAL DE TECIDO EPITELIAL". Um inibidor de EGFR-tirosina-quinase é usado na manufatura de um medicamento na utilização: (a) para reduzir a transformação de células ,epiteliais de um estado normal para um estado maligno em'um humano livre de câncer de mama invasivo; e/ou (b) para reduzir a transformação de células epiteliais de um estado intermediário, entre o epitélio normal e o epitélio invasivo maligno, para um estado maligno em um humano livre de câncer de mama invasivo; e/ou (c) para causar reversão substancial do tecido epitelial de volta para um estado normal a partir de um estado intermediário entre o epitélio normal e o epitélio invasivo maligno.
BR0015194-7A 1999-11-02 2000-11-01 Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial BR0015194A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use
PCT/GB2000/004190 WO2001032155A2 (en) 1999-11-02 2000-11-01 Use of egfr tyrosine kinase inhibitors for treating breast cancer

Publications (1)

Publication Number Publication Date
BR0015194A true BR0015194A (pt) 2002-06-18

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015194-7A BR0015194A (pt) 1999-11-02 2000-11-01 Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial

Country Status (21)

Country Link
US (1) US7553815B1 (pt)
EP (1) EP1272188B1 (pt)
JP (1) JP2003513035A (pt)
KR (1) KR100785359B1 (pt)
CN (1) CN1197577C (pt)
AT (1) ATE339957T1 (pt)
AU (1) AU779190B2 (pt)
BR (1) BR0015194A (pt)
CA (1) CA2389411C (pt)
CY (1) CY1106285T1 (pt)
DE (1) DE60030889T2 (pt)
DK (1) DK1272188T3 (pt)
ES (1) ES2275556T3 (pt)
GB (1) GB9925958D0 (pt)
IL (1) IL149176A0 (pt)
MX (1) MXPA02004272A (pt)
NO (1) NO323206B1 (pt)
NZ (1) NZ518696A (pt)
PT (1) PT1272188E (pt)
WO (1) WO2001032155A2 (pt)
ZA (1) ZA200203431B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101711868A (zh) 2000-05-19 2010-05-26 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050038048A1 (en) * 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
PT2305255E (pt) * 2001-12-03 2012-09-04 Bayer Healthcare Llc Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
KR20050037510A (ko) * 2002-06-05 2005-04-22 세다르스-신나이 메디칼 센터 키나제 억제제를 사용하는 암 치료 방법
EP1664716A4 (en) * 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
CN1882569B (zh) 2003-09-19 2010-09-29 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
AU2007213028C1 (en) 2006-02-09 2011-05-19 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN102421427B (zh) * 2009-03-11 2013-11-06 阿迪生物科学公司 用于治疗特定癌症的包含rdea119/bay869766的药物组合
MX2011009729A (es) 2009-03-20 2011-10-14 Genentech Inc Anticuerpos anti-her.
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP2014526891A (ja) 2011-08-17 2014-10-09 ジェネンテック， インコーポレイテッド ニューレグリン抗体とその使用
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
MX9709867A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
DK0836605T3 (da) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
IL139707A0 (en) * 1998-05-15 2002-02-10 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
DE602007005815D1 (de) 2006-08-28 2010-05-20 Koninkl Philips Electronics Nv Verfahren und vorrichtung zur bilderweiterung

Also Published As

Publication number Publication date
CA2389411A1 (en) 2001-05-10
JP2003513035A (ja) 2003-04-08
GB9925958D0 (en) 1999-12-29
NO20022065L (no) 2002-06-24
ES2275556T3 (es) 2007-06-16
WO2001032155A3 (en) 2002-05-10
CN1197577C (zh) 2005-04-20
AU779190B2 (en) 2005-01-13
DE60030889T2 (de) 2007-04-05
ATE339957T1 (de) 2006-10-15
ZA200203431B (en) 2003-02-26
CY1106285T1 (el) 2011-10-12
AU1155901A (en) 2001-05-14
NO20022065D0 (no) 2002-04-30
MXPA02004272A (es) 2003-08-20
WO2001032155A2 (en) 2001-05-10
DE60030889D1 (de) 2006-11-02
NO323206B1 (no) 2007-01-22
CA2389411C (en) 2009-09-01
CN1387437A (zh) 2002-12-25
EP1272188B1 (en) 2006-09-20
PT1272188E (pt) 2007-01-31
EP1272188A2 (en) 2003-01-08
US7553815B1 (en) 2009-06-30
NZ518696A (en) 2004-12-24
KR20020064306A (ko) 2002-08-07
DK1272188T3 (da) 2007-01-29
KR100785359B1 (ko) 2007-12-18
IL149176A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
BR0015194A (pt) Uso de um inibidor de egfr-tirosina-quinase, e, métodos para redução da transformação de células epiteliais e para causar reversão substancial de tecido epitelial
BR9916768A (pt) Métodos para produção de rádio-223 para usosbiomédicos e para tratamento profilático outerapêutico de doneça não maligna ou malignaafetando os ossos e tecidos macios em ummamìfero, preparação fisiologicamente aceitávelpara administração in vivo, uso de rádio-223, e, kit
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
BR0206985A (pt) Anticorpos modificados e métodos de uso
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ATE365543T1 (de) Tablettierung verdickender systeme
BR9910251A (pt) Estimulação hematopoiética
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
FI956014A (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
CA2396186A1 (en) Agents for the treatment of skin disorders
SE9900961D0 (sv) Novel compounds
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
SE9802208D0 (sv) Novel compounds
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
AR037343A1 (es) Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
BR0214798A (pt) Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
ATE239781T1 (de) Immortalisierte menschliche prostata- epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
SV2002000179A (es) Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el
IT1292092B1 (it) Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
SE9504662D0 (sv) New compounds
PT1255538E (pt) Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.